BioSpace News Archive

LabCorp (NYSE: LH) today announced that members of the executive management team will participate in a virtual fireside chat at the 29 th Annual Credit Suisse Virtual Healthcare Conference on Monday, Nov. 9 at 8:00 a.m. ET. A live audio webcast of the presentation will be available via the company website at www.LabCorp.com and archived for replay. About LabCorp LabCorp (NYSE: LH), an S&P 500 comp

Intersect ENT, Inc., a company transforming care for patients with ear, nose and throat conditions, reported financial results for the third quarter ended September 30, 2020.

Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended September 30, 2020. Clinical p rogram update Roluperidone The U.S. Food and Drug Administration (FDA) has granted Minerva a Type C meeting scheduled to take place via teleconference o

Kaleido Biosciences, Inc. (Nasdaq: KLDO) today announced financial results for the third quarter 2020 and provided a corporate update. “Kaleido continues to build momentum with the development of interventions based on our Microbiome Metabolic Therapy, or MMT™, platform and evaluate the highly diverse applications of

Data to Support MindMed’s Project Lucy in Preparing Phase 2b Trial for Anxiety Disorders

- Submission of chemistry, manufacturing and controls (CMC) and administrative information modules represent completion of the Company’s BLA submission for teplizumab -

ChemoCentryx, Inc., announced that the Company’s third quarter 2020 financial results will be released after market close on Monday, November 9, 2020.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the publication of a peer-reviewed health-economic study

Initiation of Phase 2b clinical trial evaluating AB201 as a potential treatment for COVID 19 anticipated in fourth quarter Topline data from trial anticipated Q2 2021

Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted three new employees non-qualified stock options to purchase an aggregate of 138,500 shares of Calithera’s common stock, at a per share exercise price of $3.54, the closing trading price on October 30, 2020.